Imeglimin
| 150px | |
| Names | |
|---|---|
| IUPAC name
(2S)-N6,N6,2-Trimethyl-1,2-dihydro-1,3,5-triazine-4,6-diamine
|
|
| Identifiers | |
| 775351-65-0 | |
| ChemSpider | 26232690 |
| Jmol 3D model | Interactive image |
|
|
|
|
| Properties | |
| C6H13N5 | |
| Molar mass | 155.21 g·mol−1 |
| Vapor pressure | {{{value}}} |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
| Infobox references | |
Imeglimin is an experimental drug being developed as an oral anti-diabetic. It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion. It will be the first of a new class of anti-diabetic if it is approved.
Imeglimin is in development (completed phase IIb clinical trials) for use both as monotherapy and in combination with other type-2 diabetes treatments.[1][2]
Various research protocols are being known through various scientists. Early studies showed that imeglimin is as effective as metformin in regulating glycaemic control.[3]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ http://www.reuters.com/article/2013/03/07/idUSnHUGGg5Jta+1e4+ONE20130307
- ↑ http://www.omicsonline.org/2155-6156/2155-6156-2-126.php#1
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
